Sarepta Therapeutics, Inc.

SRPTleader

Sarepta Therapeutics is the leader in treatments for Duchenne muscular dystrophy (DMD) — a fatal muscle-wasting disease affecting young boys. Its gene therapy Elevidys is the first approved treatment to address the genetic root cause.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($1.9B)

静态数据（加载实时财务…）

Elevidys (40%)

Exondys 51 + Other Exon Skipping (60%)

业务板块构成与主要客户

产品详情

Elevidys (Delandistrogene Moxeparvovec)55%

First FDA-approved gene therapy for Duchenne muscular dystrophy — one-time treatment targeting the root cause.

Exon Skipping Drugs (Exondys/Vyondys/Amondys)45%

Exon 51/53/45 skipping drugs — monthly IV infusions for specific DMD mutations.

供应链关系

合作伙伴

roche

Elevidys co-promotion (Roche/Genentech in ex-US)

影响: significant

宏观与市场背景

헬스케어行业新闻

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化剂

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

点击「获取 AI 分析」以获得 Sarepta Therapeutics, Inc. 的 AI 供应链分析。

企业信息

总部

Cambridge, MA

成立时间

1980

员工人数

1,900

官网

sarepta.com

行业概况 — 헬스케어

行业新闻